China===National Medical Products Administration
Tracked across 2 events · 14 articles · First seen Feb 09, 2026 · Last active Mar 21, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Regulatory
The China===National Medical Products Administration (NMPA) of China designated the Biologics License Application for Leqembi's subcutaneous formulation for Priority Review, which will accelerate its potential approval and market entry in China.
Feb 09, 2026 · 7 articles
Regulatory
The China===National Medical Products Administration (NMPA) granted priority review for InnoCare Pharma's zurletrectinib, accelerating its potential approval for pediatric use. This action highlights the NMPA's role in regulating and facilitating drug development in China.
Mar 02, 2026 · 7 articles
InnoCare Pharma
regulated by
↔
China===National Medical Products Administration
InnoCare Pharma's drug approvals are regulated by the China===National Medical P
China===Center for Drug Evaluation
part of
↔
China===National Medical Products Administration
The China===Center for Drug Evaluation is a key part of the China===National Med
NEWSDESK
Track China===National Medical Products Administration live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard